2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-161804
    GNF-2-deg 98%
    GNF-2-deg is a PROTAC degrader for dengue virus envelope protein (DENV E protein) with DC50 of 0.83 μM. GNF-2-deg prevents viral entry by inhibiting E-mediated membrane fusion, prevents virion production by protein degradation, and thereby exhibits antiviral activity against DENV 2 with EC90 of 3.5 μM. GNF-2-deg exhibits antiviral activity against ZIKV, JEV, WNV and YFV with EC90 of 1.96-7.79 μM. (Pink: ligand for target protein (HY-161805); Black: linker (HY-42149); Blue: ligand for E3 ligase (HY-23095))
    GNF-2-deg
  • HY-161805
    GNF-2-acid 714962-05-7 98%
    GNF-2-acid is a target protein ligand activity control that can be used for the synthesis of PROTACs (HY-161806) .
    GNF-2-acid
  • HY-161807
    DENV ligand 1 1628758-48-4 98%
    DENV ligand 1 is a ligand for DENV E protein. DENV ligand 1 can be utilized for synthesis of PROTAC Degrader ZXH-8-004 (HY-161806).
    DENV ligand 1
  • HY-161808
    DENV ligand 2 98%
    DENV ligand 2 is the ligand for DENV E protein.DENV ligand 2 can be utilized for synthesis of PROTAC Degrader ZXH-8-004 (HY-161806). DENV ligand 2 is the active form of DENV ligand 1 (HY-161807).
    DENV ligand 2
  • HY-161813
    Antibacterial agent 229 3049500-54-8 98%
    Antibacterial agent 229 (compound 8a) is a potent antibacterial agent. Antibacterial agent 229 shows antibacterial and antifungal abilities. Antibacterial agent 229 disrupts the integrity of the bacterial membrane, intercalates into DNA. Antibacterial agent 229 inhibits topoisomerase IV with an IC50 value of 10.88 µM.
    Antibacterial agent 229
  • HY-161820
    IAV-IN-3 3049492-11-4 98%
    IAV-IN-3 (Compound (R,S)-16s) is an anti-influenza A virus (IAV) agent (EC50 = 0.134 μM) with weak cytotoxicity (CC50 = 15.35 μM for MDCK cells). IAV-IN-3 inhibits IAV polymerase with an IC50 of 0.045 μM.
    IAV-IN-3
  • HY-161822
    Antibacterial agent 230 3049368-26-2 98%
    Antibacterial agent 230 (compound 10) is an effective Antifungal agent. The MIC value of antibacterial agent 230 against fluconazole-resistant fungi is 2.0 ~ 16.0 μg/mL.
    Antibacterial agent 230
  • HY-161827
    Anti-MRSA agent 14 3050586-22-3 98%
    Anti-MRSA agent 14 (Compound C17) has antibacterial agent against MRSA and MRSA-infected skin murine model. Anti-MRSA agent 14 is more potential than Norfloxacin (HY-B0132) against MRSA. Anti-MRSA agent 14 disrupts cell membrane and restrains metabolism. Anti-MRSA agent 14 shows antibacterial effects against S. aureus ATCC 6538, S. aureus ATCC 29213, S. epidermidis ATCC 12228, and MRSA with MIC values of 1, 2, 2, 1 μM respectively.
    Anti-MRSA agent 14
  • HY-161837
    SARS-CoV-2 Mpro-IN-24 98%
    SARS-CoV-2 Mpro-IN-24 (Compound X77) is a inhibitor of SARS-CoV-2 Mpro (IC50=2.8 μM) and also a non-covalent inhibitor of SARS-CoV Mpro (IC50=3.4 μM).
    SARS-CoV-2 Mpro-IN-24
  • HY-161905
    ML471 2226227-77-4 98%
    ML471 is an oral active parasite tyrosyl-tRNA synthetase (PfTyrRS) inhibitor and can be used for study of malaria.
    ML471
  • HY-161935
    6-(12-Tridecene-1-yl)-2,4-Dihydroxy benzoic acid 98%
    6-(12-Tridecene-1-yl)-2,4-Dihydroxy benzoic acid (Compound 2) exhibits antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) and Vancomycin enterococci (VRE). 6-(12-Tridecene-1-yl)-2,4-Dihydroxy benzoic acid interfers with the integrity and function of the bacterial cell membrane, and affects metabolism in MRSA. 6-(12-Tridecene-1-yl)-2,4-Dihydroxy benzoic acid exhibits anti-inflammatory and anti-infective efficacy, and promotes angiogenesis in mice.
    6-(12-Tridecene-1-yl)-2,4-Dihydroxy benzoic acid
  • HY-161937
    Antibacterial agent 236 2364479-10-5 98%
    Antibacterial agent 236 (Compound 4l) is an orally active inhibitor for DNA gyrase and topoisomerase IV (IC50 is 3.2 and 300 nM in Staphylococcus aureus), and exhibits board-spectrum antibacterial activity. Antibacterial agent 236 exhibits good pharmacokinetic properties in mice.
    Antibacterial agent 236
  • HY-161955
    TMV-IN-11 2991481-09-3 98%
    TMV-IN-11 (compound syn-3g) is a potent TMV inhibitor with high inactivation capacity (IC50: 120.7 μg/mL). TMV-IN-11 can effectively inhibit the expression of TMV.
    TMV-IN-11
  • HY-161956
    Antiviral agent 59 3054659-65-0 98%
    Antiviral agent 59 (compound 58) is an antiviral agent with selective and drug-like properties that inhibits a broad spectrum of filoviruses. Antiviral agent 59 exhibits low off-target activity and inhibition against replication-competent Ebola virus (EBOV), Sudan virus (SUDV), and Marburg virus (MARV/b>).
    Antiviral agent 59
  • HY-161987
    LpxH-IN-2 2923230-41-3 98%
    LpxH-IN-2 (compound 014) is a potent LpxH inhibitor. LpxH-IN-2 shows antibacterial activity for E. coli.
    LpxH-IN-2
  • HY-161988
    Antimicrobial agent-34 3055131-42-2 98%
    Antimicrobial agent-34 (compound 4h) is an antibacterial agent (MIC = 1–4 μg/mL), with a clogP value of 9.14. Antimicrobial agent-34 has good plasma stability (HC50 of 131.1 μg/mL) and good membrane selectivity (HC50/MIC is 65.6), with rapid sterilization capability. Antimicrobial agent-34 destroys the integrity of bacterial cell membranes, induces an increase in intracellular reactive oxygen species, and leaks protein and DNA, ultimately leading to bacterial death. Antimicrobial agent-34 demonstrates significant in vivo antibacterial potency in a mouse sepsis model infected with Staphylococcus aureus ATCC43300.
    Antimicrobial agent-34
  • HY-162022
    BTA-188 314062-80-1 98%
    BTA-188, a pyridazinyl oxime ether, is an orally active, potent inhibitor of rhinoviruses (HRV) and enterovirus (EV) 71 in vitro. BTA-188 inhibits HRV-2 replication with an IC50 of 0.8 nM and an IC90 of 11 nM. BTA-188 inhibits enterovirus with an IC50 of 82 and an IC90 of 109 nM. BTA-188 is a potential chemotherapeutic agent for infections caused by the viruses in the Picornaviridae.
    BTA-188
  • HY-162028
    GaMF1.39 2568607-82-7 98%
    GaMF1.39 is an antimycobacterial compound, targeting the F-ATP synthase subunit γ. GaMF1.39 displays enhanced anti-tuberculosis activity in combination with ETC inhibitors.
    GaMF1.39
  • HY-162087
    FabH-IN-2 3040281-87-3 98%
    FabH-IN-2 (25), an antimicrobial agent, exhibits remarkable potential as an agent with an MIC range of 1.25-3.13 μg/mL against the tested bacterial strains and an IC50 of 2.0 μM against E. coli-derived FabH.
    FabH-IN-2
  • HY-162094
    Antitubercular agent-44 3027135-80-1 98%
    Antitubercular agent-44 (compound 21b) has anti-tuberculosis (H37Rv MIC = 0.06 μM). Antitubercular agent-44 has oral activity.
    Antitubercular agent-44
Cat. No. Product Name / Synonyms Application Reactivity